| Recruiting | Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management Breast Cancer Stage IV | Phase 2 | 2026-02-18 |
| Recruiting | Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic B Metastatic Breast Cancer | — | 2025-05-20 |
| Recruiting | HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan Breast Cancer Stage IV | Phase 2 | 2024-03-15 |
| Recruiting | Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cance Metastatic Prostate Cancer | — | 2023-03-28 |
| Active Not Recruiting | Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor | Phase 2 | 2023-02-03 |
| Active Not Recruiting | NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk Breast Cancer | Phase 2 | 2022-11-25 |
| Recruiting | Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer Breast Cancer Stage II | Phase 2 | 2022-05-03 |
| Active Not Recruiting | Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype Metastatic Breast Cancer | Phase 3 | 2022-03-28 |
| Completed | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast HER2-negative Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer | Phase 2 | 2022-03-25 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma | Phase 2 | 2021-04-12 |
| Active Not Recruiting | Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic B Breast Cancer | Phase 2 | 2021-03-15 |
| Completed | Elacestrant in Preoperative Setting, a Window of Opportunity Study Breast Cancer, Hormone Receptor Positive Breast Carcinoma | EARLY_Phase 1 | 2021-02-09 |
| Unknown | A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer A Breast Cancer | EARLY_Phase 1 | 2020-12-22 |
| Completed | Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer Breast Cancer | EARLY_Phase 1 | 2020-11-06 |
| Active Not Recruiting | Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast C Metastatic Breast Cancer | — | 2020-10-20 |
| Terminated | Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Met Breast Cancer | Phase 2 | 2020-07-23 |
| Terminated | Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor P Metastatic Breast Cancer | Phase 2 | 2020-07-21 |
| Terminated | Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metas Breast Cancer | Phase 2 | 2020-06-01 |
| Completed | Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients Metastatic Breast Cancer | Phase 1 | 2020-02-25 |
| Active Not Recruiting | HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; D Metastatic Cancer | N/A | 2019-12-13 |
| Completed | Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy Breast Cancer | EARLY_Phase 1 | 2019-11-21 |
| Completed | Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer Breast Cancer | EARLY_Phase 1 | 2018-12-10 |
| Completed | Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. Breast Cancer | Phase 2 | 2017-07-13 |
| Completed | Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients ( Breast Cancer | EARLY_Phase 1 | 2016-07-01 |
| Completed | Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer Metastatic Breast Cancer | Phase 2 | 2015-07-01 |
| Completed | SOLTI Breast Cancer Molecular Screening Program (AGATA) Metastatic Breast Cancer | — | 2014-10-01 |
| Completed | PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast C Breast Cancer | Phase 2 | 2013-10-01 |
| Completed | Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer Breast Cancer | Phase 2 | 2013-06-01 |
| Completed | Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer Breast Cancer | Phase 2 | 2012-08-01 |
| Completed | Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer Breast Cancer | — | 2012-06-01 |
| Completed | A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer Breast Cancer | Phase 2 | 2012-06-01 |
| Completed | Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Breast Cancer | Phase 2 | 2007-09-01 |